Tags : Expands

Roche Expands its MS Portfolio with the Initiation of P-III

Shots: Roche has initiated the P-III program for fenebrutinib (BTK inhibitor) in RMS and PPMS which include two identical P-III trials in RMS (FENhance 1& FENhance 2) and one P-III trial in PPMS (named FENtrepid). The studies target clinical disability progression and have a 1EPs of 12wks. cCDP-12, with the addition of a co-primary endpoint […]Read More

AstraZeneca Expands Supply Agreement with Oxford Biomedica for AZD1222 to

Shots: The companies have signed an 18mos. supply agreement under a 3yrs. master supply and development agreement. Oxford Biomedica to receive $17.95M up front as a capacity reservation fee and expects to receive additional revenue of $41.89M + materials costs for the manufacturing of multiple large-scale batches of AZD1222 until the end of 2021 Oxford […]Read More

AstraZeneca Expands the Development of AZD1222 into P-III Study in

Shots: AstraZeneca has expanded the development of AZD1222 into P-III D8110C00001 study to assess its safety, efficacy, and immunogenicity. BARDA has funded the P-III study to accelerate the development of the vaccine The P-III D8110C00001 study involves assessing of AZD1222 vs PBO for the prevention of COVID-19, in up to 30,000 participants aged ≥ 18yrs. […]Read More

Roche Expands its Collaboration with Immunomedics to Evaluate Tecentriq Based

Shots: The companies extend their existing collaboration to evaluate Immunomedics’ Trodelvy (sacituzumab govitecan-hziy) in combination with Tecentriq (atezolizumab) in patients with mUC and mNSCLC. The partners have ongoing collaboration in 1L metastatic triple-negative BC Roche will conduct two P-Ib/II studies utilizing MORPHEUS platform. The MORPHEUS-mUC study will evaluate Tecentriq + Trodelvy vs Tecentriq as monothx. […]Read More

Schrodinger Expands its Drug Discovery Efforts Against COVID-19 Deploying Parallel

Shots: Schrodinger expands its work to discover novel antiviral therapies for COVID-19 as a part of a philanthropic global initiative. The accelerated pace includes the evaluation of billions of molecules/ week and is supported by Google Cloud which provides its high-powered parallel computing enabling the rapid exploration of chemical space Schrodinger has evaluated four different […]Read More

Sanofi Expands its 2018 Collaboration with Translate Bio to Develop

Shots: Translate Bio to receive $425M up front consisting $300M in cash and $125M as equity investment at $25.59/ share representing a 50% premium to the 20-day moving average share price prior to signing. The company will receive ~$1.9B as milestones, including $450M milestones under the 2018 agreement and expects $360M in next few years […]Read More

Skyhawk Therapeutics Expands its Agreement with Merck to Develop Novel

Shots: Skyhawk will deploy its SkySTARTM platform to develop drug candidates targeting autoimmune and metabolic diseases and will receive an up front $600M/target while Merck get an option to exclusively license WW IP rights to candidates, discovered and developed under the agreement If Merck exercises its option, Skyhawk will receive an option fees, milestones and […]Read More